【摘要】：目的觀察斑蝥素酸鎂對(duì)SMMC-7721肝癌細(xì)胞絲裂原激活蛋白激酶(MAPK)信號(hào)通路的影響,探討斑蝥素酸鎂的抗癌機(jī)制。方法使用蛋白磷酸酶2A(PP2A)活性檢測(cè)試劑盒分別檢測(cè)斑蝥素酸鎂和岡田酸(OA)對(duì)PP2A活性的影響。實(shí)時(shí)定量PCR檢測(cè)斑蝥素酸鎂、OA對(duì)SMMC-7721人肝癌細(xì)胞胞外信號(hào)調(diào)節(jié)激酶1/2(ERK1/2)、p38MAPK、c-Jun N末端激酶1/2(JNK1/2)mRNA表達(dá)水平的影響;Western blot法檢測(cè)斑蝥素酸鎂、OA對(duì)SMMC-7721細(xì)胞ERK1/2、p38MAPK、JNK蛋白表達(dá)以及蛋白磷酸化水平的影響。結(jié)果 0.283μmol/L斑蝥素酸鎂對(duì)PP2A活性無(wú)明顯抑制作用,0.567μmol/L斑蝥素酸鎂能顯著抑制PP2A活性,且隨著藥物濃度的增加,抑制作用愈趨明顯;同時(shí)0.059 nmol/L OA對(duì)PP2A活性也有顯著抑制作用。與空白對(duì)照組比較,0.283μmol/L斑蝥素酸鎂組ERK1、ERK2 mRNA表達(dá)量無(wú)明顯變化,當(dāng)濃度為0.567μmol/L時(shí),ERK1、ERK2mRNA表達(dá)量顯著下降,且隨著藥物濃度的增加下降更明顯;而0.059 nmol/L OA組ERK1、ERK2 mRNA表達(dá)量卻顯著升高。0.059 nmol/L OA和不同濃度斑蝥素酸鎂組的p38MAPK、JNK1、JNK2 mRNA表達(dá)量均顯著升高。與空白對(duì)照組比較,0.283μmol/L斑蝥素酸鎂組ERK1/2磷酸化水平無(wú)明顯變化,高于0.567μmol/L斑蝥素酸鎂處理顯著下調(diào)ERK1/2磷酸化水平,其下調(diào)程度具有濃度依賴效應(yīng);而0.059 nmol/L OA組ERK1/2磷酸化水平卻顯著上調(diào)。0.059 nmol/L OA和不同濃度斑蝥素酸鎂組的p38MAPK、JNK磷酸化水平均顯著上調(diào)。結(jié)論斑蝥素酸鎂可能是通過(guò)抑制PP2A活性進(jìn)而抑制ERK1/2通路來(lái)實(shí)現(xiàn)對(duì)SMMC-7721肝癌細(xì)胞增殖的抑制作用。
[Abstract]:Objective to investigate the effect of magnesium cantharidin on mitogen-activated protein kinase (MAPK) signaling pathway in SMMC-7721 hepatoma cell line and to explore the anticancer mechanism of magnesium cantharidin. Methods protein phosphatase 2A (PP2A) activity assay kit was used to detect the effects of Cantharidin magnesium and Okadaic acid (OA) on PP2A activity. Effects of Cantharidin magnesium Oligonidate on the expression of extracellular signal-regulated kinase 1 / 2 (ERK1 / 2) p38MAPKnc-Jun N-terminal kinase 1 / 2 (JNK1 / 2) mRNA in SMMC-7721 human hepatocarcinoma cell line SMMC-7721 by real-time quantitative PCR. The effects of cantharidin magnesium aspartate OA on the expression of ERK1 / 2p38MAPKNK JNK protein and protein phosphorylation in SMMC-7721 cells were detected by Western blot. Results magnesium cantharidate (0.283 渭 mol / L) had no obvious inhibitory effect on PP2A activity. Magnesium cantharidate (0.567 渭 mol / L) could significantly inhibit PP2A activity, and the inhibitory effect increased with the increase of drug concentration, and 0.059 nmol / L OA had a significant inhibitory effect on PP2A activity. Compared with the control group, the expression of ERK1 ERK2 mRNA in 0.283 渭 mol / L magnesium cantharidate group had no significant change, and the expression of ERK1 ERK2 mRNA decreased significantly when the concentration was 0.567 渭 mol / L, and the decrease was more obvious with the increase of drug concentration. However, the expression of ERK1 + ERK2 mRNA in 0.059 nmol / L OA group was significantly higher than that in the control group. The expression of p38 MAPK1 JNK1 JNK2 mRNA was significantly increased in the 0.059 nmol / L OA group and in the different concentration of magnesium cantharidate group. Compared with the blank control group, the phosphorylation level of ERK1 / 2 in the 0.283 渭 mol / L magnesium cantharidate group did not change significantly, but was significantly lower than that in the 0.567 渭 mol / L magnesium cantharidate group, and the down-regulation was concentration-dependent. However, the phosphorylation level of ERK1 / 2 in 0.059 nmol / L OA group was significantly higher than that in 0.059 nmol / L OA group and p38 MAPKN JNK phosphorylation level in different concentration magnesium cantharidate group. Conclusion magnesium cantharidate may inhibit the proliferation of SMMC-7721 hepatoma cells by inhibiting PP2A activity and ERK1 / 2 pathway.
【作者單位】： 遵義醫(yī)學(xué)院貴州省普通高等學(xué)校特色藥物腫瘤防治特色重點(diǎn)實(shí)驗(yàn)室;遵義醫(yī)學(xué)院基礎(chǔ)醫(yī)學(xué)院;
【基金】：國(guó)家自然科學(xué)基金(81560669,81260488) 貴州省科技合作計(jì)劃項(xiàng)目(黔科合LH字[2015]7509號(hào),黔科合LH字[2015]7516號(hào)) 貴州省科技廳中藥現(xiàn)代化項(xiàng)目(黔科合ZY字[2013]3012) 貴州省衛(wèi)計(jì)委科學(xué)基金項(xiàng)目(gzwjk2015-1-013) 醫(yī)學(xué)昆蟲(chóng)資源開(kāi)發(fā)利用創(chuàng)新團(tuán)隊(duì)(黔合教人才團(tuán)隊(duì)字[2014]39號(hào)) 貴州省教育廳特色重點(diǎn)實(shí)驗(yàn)室建設(shè)項(xiàng)目(黔教合KY字[2014]212)
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 楊清林;李勝容;王賢英;;斑蝥中斑蝥素的提取工藝研究[J];重慶中草藥研究;2010年01期

2 楊清林;李勝容;王賢英;韋垎;蔣成英;;不同產(chǎn)地斑蝥中斑蝥素的測(cè)定[J];重慶中草藥研究;2010年01期

3 陳運(yùn)久,劉傳華,陳滬寧;氣相色譜法測(cè)定斑蝥體內(nèi)的斑蝥素含量[J];山東中醫(yī)雜志;2001年04期

4 吳建梅,任天池,虞梅;去甲基斑蝥素的藥學(xué)研究與臨床應(yīng)用進(jìn)展[J];中國(guó)藥學(xué)雜志;2002年08期

5 安琳娜;黨云潔;朱春燕;;斑蝥素β-環(huán)糊精包合物的研究[J];中國(guó)藥學(xué)雜志;2009年13期

6 王正;安中原;王東;尹永芹;趙越;;氣相色譜內(nèi)標(biāo)法測(cè)定斑蝥中斑蝥素的含量[J];中國(guó)中藥雜志;2009年16期

7 王賢英;楊瓊芳;謝香菊;;不同提取方法對(duì)斑蝥中斑蝥素含量測(cè)定的影響[J];中成藥;2010年05期

8 胡朝陽(yáng);;斑蝥素含量測(cè)定方法研究進(jìn)展[J];廣州化工;2011年10期

9 王賢英;楊瓊芳;謝香菊;;不同提取方法對(duì)斑蝥中斑蝥素含量測(cè)定的影響[J];重慶中草藥研究;2011年01期

10 武增玉;徐長(zhǎng)青;宋慧芳;黃淑鳳;;斑蝥中斑蝥素的提取工藝研究考察[J];山西中醫(yī);2011年09期

相關(guān)會(huì)議論文 前10條

1 汪麗;陳利平;張來(lái)喜;楊寶東;張愛(ài)環(huán);張民照;王進(jìn)忠;張志勇;;斑蝥素的毒理機(jī)制研究進(jìn)展[A];公共植保與綠色防控[C];2010年

2 周游;朱芬;牛長(zhǎng)纓;雷朝亮;;斑蝥素抗腫瘤作用的研究[A];華中昆蟲(chóng)研究（第五卷）[C];2008年

3 李慧;方清影;臧琛;張保獻(xiàn);聶其霞;王國(guó)華;;斑蝥素非離子表面活性劑囊泡的制備及其體外特性表征[A];2010年全國(guó)中藥學(xué)術(shù)研討會(huì)論文集[C];2010年

4 李海生;周靜遠(yuǎn);;羥基斑鍪胺中斑蝥素的高效液相色譜測(cè)定法[A];天津市色譜研究會(huì)第一屆學(xué)術(shù)報(bào)告會(huì)論文、報(bào)告（摘要）匯集[C];1980年

5 郭常q，

本文編號(hào)：2131830